Patents by Inventor Maurice Scott Swanson

Maurice Scott Swanson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11529358
    Abstract: Disclosed are methods of treating a disorder or disease associated with myotonic dystrophy. Methods of treating a CNS dysfunction and/or cognitive impairment associated with myotonic dystrophy in a subject comprising administering a therapeutically effective amount of a GABAA receptor antagonist or inverse agonist to the subject are disclosed. Methods of treating a myotonic dystrophy associated disease or disorder caused by mis-splicing of GABRG2 in a subject comprising administering a therapeutically effective amount of a GABAA receptor antagonist or inverse agonist to the subject are disclosed. Methods of improving cognitive function or alertness in a subject having myotonic dystrophy comprising administering a therapeutically effective amount of a GABAA receptor antagonist or inverse agonist to the subject are disclosed.
    Type: Grant
    Filed: May 10, 2018
    Date of Patent: December 20, 2022
    Assignees: Emory University, University of Florida Research Foundation, Inc.
    Inventors: Gary Bassell, Andrew Jenkins, David B. Rye, Maurice Scott Swanson, Eric Tzy-Shi Wang, Lyndon Lien
  • Publication number: 20210023091
    Abstract: Disclosed are methods of treating a disorder or disease associated with myotonic dystrophy. Methods of treating a CNS dysfunction and/or cognitive impairment associated with myotonic dystrophy in a subject comprising administering a therapeutically effective amount of a GABAA receptor antagonist or inverse agonist to the subject are disclosed. Methods of treating a myotonic dystrophy associated disease or disorder caused by mis-splicing of GABRG2 in a subject comprising administering a therapeutically effective amount of a GABAA receptor antagonist or inverse agonist to the subject are disclosed. Methods of improving cognitive function or alertness in a subject having myotonic dystrophy comprising administering a therapeutically effective amount of a GABAA receptor antagonist or inverse agonist to the subject are disclosed.
    Type: Application
    Filed: May 10, 2018
    Publication date: January 28, 2021
    Inventors: Gary BASSELL, Andrew JENKINS, David B. RYE, Maurice Scott SWANSON, Eric Tzy-Shi WANG, Lyndon LIEN
  • Patent number: 9371527
    Abstract: Disclosed are compositions and methods related to the interaction of polyCUG and polyCCUG repeat RNA and proteins that bind to these repetitive RNA sequences. Also disclosed are methods of treating DM1 or DM2 comprising inhibiting the interaction of poly(CUG)exp or poly(CCUG)exp RNA with muscleblind proteins, or by causing improvement of spliceopathy in myotonic dystrophy.
    Type: Grant
    Filed: June 5, 2014
    Date of Patent: June 21, 2016
    Assignee: University of Rochester
    Inventors: Charles A. Thornton, Thurman Wheeler, Krzysztof Sobczak, Robert Osborne, Jill Miller, Maurice Scott Swanson
  • Publication number: 20150080452
    Abstract: Disclosed are compositions and methods related to the interaction of polyCUG and polyCCUG repeat RNA and proteins that bind to these repetitive RNA sequences. Also disclosed are methods of treating DM1 or DM2 comprising inhibiting the interaction of poly(CUG)exp or poly(CCUG)exp RNA with muscleblind proteins, or by causing improvement of spliceopathy in myotonic dystrophy.
    Type: Application
    Filed: June 5, 2014
    Publication date: March 19, 2015
    Inventors: Charles A. Thornton, Thurman Wheeler, Krzysztof Sobczak, Robert Osborne, Jill Miller, Maurice Scott Swanson